Stifel analyst Rick Wise maintains $GE HealthCare Technologies (GEHC.US)$ with a buy rating, and adjusts the target price from $100 to $102.
According to TipRanks data, the analyst has a success rate of 58.6% and a total average return of 4.4% over the past year.
Furthermore, according to the comprehensive report, the opinions of $GE HealthCare Technologies (GEHC.US)$'s main analysts recently are as follows:
GE HealthCare shares have ascended by 20% since the beginning of the year and are approaching record levels. They are currently valued at a 5% premium compared to their close peer, Siemens Healthineers, which contrasts with their usual 18-month average discount of 15%. This valuation seems challenging to justify in light of GE HealthCare's diminished growth prospects, suggesting that investor expectations might surpass even those of sell-side consensus. It is anticipated that GE's growth in the near to medium term may not meet expectations.
GE HealthCare experienced positive developments with the FDA's approval of Flurpiridaz, a pioneering myocardial perfusion imaging PET radiopharmaceutical that is produced as an 'individual dose' beforehand, in contrast to the current requirement for on-site manufacturing. Analysts suggest that due to its notable clinical advantages over other MPI radiopharmaceuticals, Flurpiridaz is expected to be rapidly adopted by existing cardiac PET centers in the U.S., potentially broadening the access to cardiac PET significantly.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
斯迪富分析師Rick Wise維持$GE HealthCare Technologies (GEHC.US)$買入評級，並將目標價從100美元上調至102美元。
根據TipRanks數據顯示，該分析師近一年總勝率為58.6%，總平均回報率為4.4%。
此外，綜合報道，$GE HealthCare Technologies (GEHC.US)$近期主要分析師觀點如下：
自年初以來，通用電氣醫療的股價上漲了20％，並接近創紀錄的水平。與其近親西門子Healthineers相比，他們目前的估值溢價爲5％，而通常的18個月平均折扣爲15％。鑑於GE Healthcare的增長前景黯淡，這一估值似乎很難證明其合理性，這表明投資者的預期甚至可能超過賣方共識。預計通用電氣在短期至中期內的增長可能無法達到預期。
GE Healthcare取得了積極進展，美國食品藥品管理局批准了Flurpiridaz。Flurpiridaz是一種開創性的心肌灌注成像pET放射藥物，事先以 「個人劑量」 的形式生產，與目前的現場生產要求形成鮮明對比。分析人士認爲，由於Flurpiridaz與其他MPI放射藥物相比具有顯著的臨床優勢，預計美國現有的心臟pET中心將迅速採用Flurpiridaz，這有可能顯著擴大獲得心臟pET的機會。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
